4.6 Article

PDE4 inhibitor eliminates breast cancer stem cells via noncanonical activation of mTOR

Journal

JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 123, Issue 12, Pages 1980-1996

Publisher

WILEY
DOI: 10.1002/jcb.30325

Keywords

autophagy; cAMP; cancer stem cells; mTOR; PDE; rolipram

Funding

  1. Department of Biotechnology, Government of West Bengal, India [248(Sanc)/BT (Estt)/RD-27/2016]

Ask authors/readers for more resources

Ineffective cancer treatment is closely related to the persistence of cancer stem cells (CSCs). The study found that the expression of phosphatidylinositol-3-kinase (PI3K) was upregulated in breast CSCs, while phosphodiesterase 4 (PDE4) levels were higher in breast CSCs compared to normal stem cells. The PDE4 inhibitor rolipram was able to induce cell cycle arrest and apoptosis in CSCs by modulating the PI3K signaling pathway.
Ineffective cancer treatment is implicated in metastasis, recurrence, resistance to chemotherapy and radiotherapy, and evasion of immune surveillance. All these failures occur due to the persistence of cancer stem cells (CSCs) even after rigorous therapy, thereby rendering them as essential targets for cancer management. Contrary to the quiescent nature of CSCs, a gene profiler array disclosed that phosphatidylinositol-3-kinase (PI3K), which is known to be crucial for cell proliferation, differentiation, and survival, was significantly upregulated in CSCs. Since PI3K is modulated by cyclic adenosine 3 ',5 ' monophosphate (cAMP), analyses of cAMP regulation revealed that breast CSCs expressed increased levels of phosphodiesterase 4 (PDE4) in contrast to normal stem cells. In accordance, the effects of rolipram, a PDE4 inhibitor, were evaluated on PI3K regulators and signaling. The efficacy of rolipram was compared with paclitaxel, an anticancer drug that is ineffective in obliterating breast CSCs. Analyses of downstream signaling components revealed a switch between cell survival and death, in response to rolipram, specifically of the CSCs. Rolipram-mediated downregulation of PDE4A levels in breast CSCs led to an increase in cAMP levels and protein kinase A (PKA) expression. Subsequently, PKA-mediated upregulation of phosphatase and tensin homolog antagonized the PI3K/AKT/mTOR pathway and led to cell cycle arrest. Interestingly, direct yet noncanonical activation of mTOR by PKA, circumventing the influence of PI3K and AKT, temporally shifted the fate of CSCs toward apoptosis. Rolipram in combination with paclitaxel indicated synergistic consequences, which effectively obliterated CSCs within a tumor, thereby suggesting combinatorial therapy as a sustainable and effective strategy to abrogate breast CSCs for better patient prognosis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available